期刊
LEUKEMIA & LYMPHOMA
卷 63, 期 9, 页码 2126-2135出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2022.2062347
关键词
Multiple myeloma; stem cell transplantation; lenalidomide; continuous induction; response-adapted therapy
资金
- National Institutes of Health/National Cancer Institute (NIH/NCI) Memorial Sloan Kettering Cancer Center Support Grant [P30 CA008748]
- Celgene Corporation
The extended follow-up analysis of a phase 2 trial showed that early responsive patients with newly diagnosed multiple myeloma can safely continue induction therapy without undergoing upfront autologous stem cell transplantation. There were no significant differences in progression-free survival, overall survival, and rates of partial response between the continued induction therapy group and the autologous stem cell transplantation group.
Although upfront autologous stem cell transplantation (ASCT) generally improves progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), the overall survival (OS) benefit and optimal timing of ASCT are not well established. Patients with early response may be able to safely continue induction and avoid ASCT without compromised outcomes. We report an extended follow-up analysis of a phase 2 trial that randomized transplant-eligible patients with NDMM who responded to induction (50/65 patients) to continued induction or ASCT; median follow-up was 8.0 years. Patients had similar 8-year PFS (55% vs. 43%), 8-year OS (83% vs. 72%), and rates of at least very good partial response (72% vs. 84%) whether continuing induction of lenalidomide and dexamethasone (Ld arm) or receiving ASCT (Ld + ASCT arm) (p = 0.5). Notably, over 50% of patients receiving continuous Ld had PFS of 5-10 years. These results suggest the need for prospective trials incorporating response-adapted therapeutic approaches to NDMM.STATEMENT OF PRIOR PRESENTATION Presented in abstract form (interim analysis) at the 56th annual meeting of the American Society of Hematology (San Francisco, CA, 6 December 2014) and at the 57th annual meeting of the American Society of Hematology (Orlando, FL, 3 December 2015).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据